{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:09:07Z","timestamp":1779912547136,"version":"3.53.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["25171"],"award-info":[{"award-number":["25171"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["173604"],"award-info":[{"award-number":["173604"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.canep.2024.102740","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T08:06:17Z","timestamp":1736841977000},"page":"102740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Glycogen synthase kinase-3\u00df inhibitor use and prostate cancer incidence in Manitoba, Canada: A population-based nested case\u2013control study"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8472-932X","authenticated-orcid":false,"given":"Christiaan H.","family":"Righolt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emrah","family":"Sever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salaheddin M.","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2024.102740_bib1","unstructured":"Canadian Cancer Statistics Advisory Committee, Canadian Cancer Statistics 2019, Toronto, ON, 2019."},{"key":"10.1016\/j.canep.2024.102740_bib2","series-title":"Progress in Cancer Prevention","first-page":"53","article-title":"The enigma of prostate cancer: an epidemiologic survey of the etiological models of prostate cancer","author":"Mahmud","year":"2008"},{"key":"10.1016\/j.canep.2024.102740_bib3","series-title":"Textbook of Cancer Epidemiology","article-title":"Prostate cancer","author":"Wilson","year":"2018"},{"key":"10.1016\/j.canep.2024.102740_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2024.102740_bib5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2024.102740_bib6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJMe1001045","article-title":"Chemoprevention of prostate cancer","volume":"362","author":"Walsh","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2024.102740_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016412","article-title":"Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study","volume":"6","author":"Mahmud","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.canep.2024.102740_bib8","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/ijc.25186","article-title":"Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis","volume":"127","author":"Mahmud","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2024.102740_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2024.102740_bib10","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1002\/ijc.25811","article-title":"Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006","volume":"128","author":"Dhillon","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2024.102740_bib11","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/jnci\/djk132","article-title":"A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence","volume":"99","author":"Jacobs","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canep.2024.102740_bib12","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1055-9965.EPI-19-0464","article-title":"Statin use and prostate cancer incidence in Manitoba, Canada: a population-based nested case\u2013control study","volume":"28","author":"Righolt","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.canep.2024.102740_bib13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ijc.31295","article-title":"The effect of statin use on the incidence of prostate cancer: a population-based nested case\u2013control study","volume":"143","author":"Dawe","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2024.102740_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046691","article-title":"Statin use and risk of prostate cancer: a meta-analysis of observational studies","volume":"7","author":"Bansal","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.canep.2024.102740_bib15","first-page":"9081","article-title":"Biologic and epidemiologic evidence assessing if statins prevent prostate cancer","volume":"24","author":"Dawe","year":"2017","journal-title":"Can. J. Urol."},{"key":"10.1016\/j.canep.2024.102740_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrurol.2016.199","article-title":"The current evidence on statin use and prostate cancer prevention: are we there yet?","volume":"14","author":"Alfaqih","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.canep.2024.102740_bib17","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4103\/1008-682X.190327","article-title":"Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review","volume":"19","author":"Tan","year":"2017","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.canep.2024.102740_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4088\/JCP.v65n0103","article-title":"Glycogen synthase kinase-3: a target for novel bipolar disorder treatments","volume":"65","author":"Gould","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.canep.2024.102740_bib19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1172\/JCI46465","article-title":"The intersection of genetic and chemical genomic screens identifies GSK-3\u03b1 as a target in human acute myeloid leukemia","volume":"122","author":"Banerji","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canep.2024.102740_bib20","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/pros.22868","article-title":"Activation of Wnt\/\u03b2-catenin signaling in a subpopulation of murine prostate luminal epithelial cells induces high grade prostate intraepithelial neoplasia","volume":"74","author":"Valkenburg","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.canep.2024.102740_bib21","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.18632\/oncotarget.3335","article-title":"Discrete functions of GSK3\u03b1 and GSK3\u03b2 isoforms in prostate tumor growth and micrometastasis","volume":"6","author":"Gao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canep.2024.102740_bib22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ejmech.2017.11.103","article-title":"Glycogen synthase kinase-3 and its inhibitors: potential target for various therapeutic conditions","volume":"144","author":"Saraswati","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canep.2024.102740_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bdi.12361","article-title":"Lithium treatment and cancer incidence in bipolar disorder","volume":"18","author":"Martinsson","year":"2016","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.canep.2024.102740_bib24","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1158\/1055-9965.EPI-08-0646","article-title":"Cancer risk in long-term users of valproate: a population-based case-control study","volume":"18","author":"Hallas","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.canep.2024.102740_bib25","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/cncr.28479","article-title":"Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer","volume":"120","author":"Kang","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.canep.2024.102740_bib26","first-page":"637","article-title":"Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study","volume":"27","author":"Salminen","year":"2016","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.canep.2024.102740_bib27","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9527920","article-title":"Use of antiepileptic drugs and risk of prostate cancer: a nationwide case-control study in prostate cancer data base Sweden","volume":"2023","author":"George","year":"2023","journal-title":"J. Oncol."},{"key":"10.1016\/j.canep.2024.102740_bib28","series-title":"The Cost of Smoking: A Manitoba Study","author":"Martens","year":"2015"},{"key":"10.1016\/j.canep.2024.102740_bib29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00005650-199303000-00002","article-title":"Registries and administrative data: organization and accuracy","volume":"31","author":"Roos","year":"1993","journal-title":"Med. Care"},{"key":"10.1016\/j.canep.2024.102740_bib30","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/00005650-199709000-00006","article-title":"Estimating the burden of disease: comparing administrative data and self-reports","volume":"35","author":"Robinson","year":"1997","journal-title":"Med. Care"},{"key":"10.1016\/j.canep.2024.102740_bib31","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1345\/aph.18117","article-title":"Validation of an electronic, population-based prescription database","volume":"32","author":"Kozyrskyj","year":"1998","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.canep.2024.102740_bib32","unstructured":"World Health Organization, International Classification of Diseases for Oncology, third ed., First Revision, Geneva, 2013."},{"key":"10.1016\/j.canep.2024.102740_bib33","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/oxfordjournals.aje.a116398","article-title":"Selection of controls in case-control studies: III. Design options","volume":"135","author":"Wacholder","year":"1992","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.canep.2024.102740_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2377-13-16","article-title":"Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance","volume":"13","author":"Marrie","year":"2013","journal-title":"BMC Neurol."},{"key":"10.1016\/j.canep.2024.102740_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.eplepsyres.2012.05.009","article-title":"Development and validation of a case definition for epilepsy for use with administrative health data","volume":"102","author":"Reid","year":"2012","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.canep.2024.102740_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/009286150403800104","article-title":"The use of the World Health Organisation anatomical therapeutic chemical\/defined daily dose methodology in Canada","volume":"38","author":"Sketris","year":"2004","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.canep.2024.102740_bib37","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2146\/ajhp070369","article-title":"Bias: considerations for research practice","volume":"65","author":"Gerhard","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.canep.2024.102740_bib38","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology, ATC\/DDD Index 2004, 2014."},{"key":"10.1016\/j.canep.2024.102740_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1353-8292(99)00008-8","article-title":"Assessing ecologic proxies for household income: a comparison of household and neighbourhood level income measures in the study of population health status","volume":"5","author":"Mustard","year":"1999","journal-title":"Health Place"},{"key":"10.1016\/j.canep.2024.102740_bib40","series-title":"Defining and Validating Chronic Diseases: An Administrative Data Approach","author":"Lix","year":"2006"},{"key":"10.1016\/j.canep.2024.102740_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00001648-199901000-00008","article-title":"Causal diagrams for epidemiologic research","volume":"10","author":"Greenland","year":"1999","journal-title":"Epidemiology"},{"key":"10.1016\/j.canep.2024.102740_bib42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ijc.33535","article-title":"Antiepileptic drugs and prostate cancer risk in the finnish randomized study of screening for prostate cancer","volume":"149","author":"Salminen","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2024.102740_bib43","series-title":"Modern Epidemiology","author":"Rothman","year":"1998"},{"key":"10.1016\/j.canep.2024.102740_bib44","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/15384047.2019.1595283","article-title":"Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses","volume":"20","author":"Sahin","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canep.2024.102740_bib45","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/0008-5472.CAN-05-0487","article-title":"Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo","volume":"66","author":"Xia","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canep.2024.102740_bib46","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/pros.20587","article-title":"Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo","volume":"67","author":"Shabbeer","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.canep.2024.102740_bib47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.21873\/invivo.11445","article-title":"The combination of metformin and valproic acid has a greater anti-tumoral effect on prostate cancer growth in vivo than either drug alone","volume":"33","author":"Tran","year":"2019","journal-title":"In Vivo"},{"key":"10.1016\/j.canep.2024.102740_bib48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13046-020-01723-7","article-title":"Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition","volume":"39","author":"Iannelli","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canep.2024.102740_bib49","first-page":"485","article-title":"Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid","volume":"18","author":"Sargazi","year":"2019","journal-title":"EXCLI J."},{"key":"10.1016\/j.canep.2024.102740_bib50","unstructured":"Statistics Canada, Diversity of the Black Population in Canada: An Overview, 2019."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782124002194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782124002194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T19:31:00Z","timestamp":1759001460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782124002194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":50,"alternative-id":["S1877782124002194"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2024.102740","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycogen synthase kinase-3\u00df inhibitor use and prostate cancer incidence in Manitoba, Canada: A population-based nested case\u2013control study","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2024.102740","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102740"}}